OTCMKTS:CNBX CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CNBX Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0063Volume3.61 million shsAverage Volume34.50 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies. Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes. The company has assembled an intellectual property portfolio covering its lead compounds and key synthetic methods, positioning its programs for potential licensing or partnership opportunities that can support late-stage development and commercialization. CNBX Pharmaceuticals’ management team brings together experts in pharmaceutical chemistry, clinical development and regulatory affairs to guide its programs through critical R&D milestones. As a clinical-stage enterprise, CNBX remains focused on advancing its lead assets toward first-in-human trials and forging strategic alliances to accelerate the delivery of next-generation cannabinoid-based therapies for patients with significant unmet medical needs.AI Generated. May Contain Errors. Read More Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNBX Stock News HeadlinesCNBX Pharmaceuticals (OTC:CNBX) Stock Quotes, Forecast and News SummaryMarch 1, 2025 | benzinga.comCNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.June 8 at 1:00 AM | Brownstone Research (Ad)CNBX Pharmaceuticals Inc CNBXNovember 5, 2023 | morningstar.comMCNBX Historical DataOctober 9, 2023 | investing.comCNBX - CNBX Pharmaceuticals Inc.July 28, 2023 | finance.yahoo.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | benzinga.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaNovember 8, 2022 | finance.yahoo.comSee More Headlines CNBX Stock Analysis - Frequently Asked Questions How have CNBX shares performed this year? CNBX Pharmaceuticals' stock was trading at $0.0004 at the beginning of 2026. Since then, CNBX stock has decreased by 50.0% and is now trading at $0.0002. When did CNBX Pharmaceuticals' stock split? CNBX Pharmaceuticals's stock reverse split on Thursday, May 12th 2022.The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram Global (OGI), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Curaleaf (CURLF), Kushco (KSHB) and Trulieve Cannabis (TCNNF). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:CNBX CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (OTCMKTS:CNBX) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersTiny Nasdaq Firm Lands €13.9 Million Semiconductor DealOne small Nasdaq-listed company just landed a 13.9 million euro contract tied to a new advanced-node semicondu...Finplays | Sponsored$36 million a day says something big is comingInstitutional capital is flowing into one thesis at a rate of $36 million per day - $25,000 every single minut...Porter & Company | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHave you tried Elon Musk’s 70X AI agent?Jeff Brown picked Nvidia in 2016 - it's up 25,155% since. He recommended Bitcoin at $240 - it's up 31,219% sin...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNBX Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.